PPH, IHE, PJP: U.S. Pharmaceutical ETFs Offer Investors Innovation and Growth

FomoAnxiety · 2026-03-02T20:25:11+00:00

U.S. pharmaceutical ETFs offer investors opportunities for growth and innovation through diversified exposure to leading companies in the sector, like Pfizer and Eli Lilly, with various fund options for investment.

FomoAnxiety

2026-03-02 20:25:11

Abstract generation in progress

Exchange-traded funds (ETFs) focused on U.S. pharmaceutical companies can offer innovation and growth to investors.

Claim 50% Off TipRanks Premium

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
Stay ahead of the market with the latest news and analysis and maximize your portfolio’s potential

It’s often said that pharmaceuticals are the most innovative area of healthcare, with companies large and small pursuing new medications and developing cutting-edge treatments for ailments ranging from cancer and arthritis to heart disease and stroke.

The U.S. pharmaceutical industry is comprised of small biotechnology firms and established companies that are known the world over, such as Pfizer PFE -1.08% ▼ and Eli Lilly LLY -2.99% ▼ . Many of these companies are steps away from the next blockbuster medication and explosive share price growth.

Leading U.S. Pharma ETFs

With the U.S. pharma sector made up of dozens of publicly traded companies, it would be easier for investors to place a bet on an ETF that is comprised of pharma stocks. These include the VanEck Pharmaceutical ETF PPH -1.04% ▼ that tracks the MVIS U.S. Listed Pharmaceutical 25 Index and has roughly $1.2 billion in assets under management.

For consideration, there is also the iShares U.S. Pharmaceuticals ETF IHE -0.45% ▼ that focuses on U.S.-based manufacturers of prescription drugs and has $959 million in assets under management. And there is the
Invesco IVZ +0.30% ▲ Pharmaceuticals ETF (PJP) that tracks U.S.-based pharmaceutical companies large and small.

Below is a chart comparing these three pharmaceutical ETFs.

Disclaimer & DisclosureReport an Issue

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.